Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VYGR

DatePrice TargetRatingAnalyst
1/10/2025Overweight
Cantor Fitzgerald
12/2/2024$12.00Buy
Citigroup
11/29/2024$7.00 → $11.00Outperform
Wedbush
10/16/2024$15.00Outperform
Leerink Partners
3/26/2024$22.00Buy
Guggenheim
3/19/2024$30.00Buy
H.C. Wainwright
3/7/2024$16.00Buy
Citigroup
1/2/2024$14.00Equal Weight → Overweight
Wells Fargo
More analyst ratings

$VYGR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

    - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

    LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease

    - Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients with early Alzheimer's disease; initial tau PET imaging data expected in H2 2026 - LEXINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced positive topline data from the Company's single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody developed to selectively inhibit the spread of pathological tau in Alzheimer's disease (AD). In the SAD trial,

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$VYGR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VYGR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VYGR
SEC Filings

See more

$VYGR
Leadership Updates

Live Leadership Updates

See more
  • Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

    LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • NorthStar Appoints Peter Pfreundschuh to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

    $FREQ
    $URGN
    $VYGR
    $IMMU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

    LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$VYGR
Financials

Live finance-specific insights

See more
  • Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

    - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer's patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results. "Over the past year, Voyager has significantly advanced our two wholly-

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

    LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Voyager Reports Third Quarter 2024 Financial and Operating Results

    - Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer's - - Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene therapy development candidate selection - - INDs on track for three CNS gene therapies in 2025 in SOD1 ALS, GBA1 Parkinson's and other GBA1-mediated disease, and Friedreich's ataxia programs - LEXINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Thera

    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$VYGR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more